Navigation Links
Synutra Annual Report on Form 10-K Includes 'Going Concern' Explanatory Paragraph from Auditor
Date:6/19/2009

QINGDAO, China and Rockville, Md. June 19 /PRNewswire-Asia/ -- Synutra International, Inc. (Nasdaq: SYUT, "Synutra"), a leading infant formula company in China, and a producer, marketer and seller of nutritional products for infants, children and adults, stated today that its Form 10-K, filed on June 15, 2009, included an unqualified audit opinion in which Synutra's independent auditor, Deloitte Touche Tohmatsu CPA Ltd. ("DTTC"), included an explanatory paragraph expressing substantial doubt regarding Synutra's ability to continue as a "going concern" in its report on Synutra's financial statements for the fiscal year ended March 31, 2009.

Liang Zhang, Chairman and CEO of Synutra, commented, "We are making efforts to overcome any doubt about our ability to continue as a going concern. We continue to pursue our market recovery strategies and to address our short-term working capital deficit head on. We are making good progress in our negotiations with ABN Amro regarding the refinancing of the original $35 million loan, and expect to commence our repayment schedule later this year. We are also currently in the process of evaluating funding alternatives, including seeking refinancing of certain of our short-term loans from PRC banks. I want to reiterate that we are increasingly confident that we can return to profitability and financial stability by the end of the current fiscal year, which ends on March 31, 2010. The rising sales and narrowing losses demonstrated in our third to fourth quarter sequential results demonstrate our progress thus far."

As a result of the melamine incident and the related product recall, Synutra experienced significant operating losses and negative cash flows from operations for the fiscal year ended March 31, 2009. In addition, the operating losses have resulted non-compliance with certain covenants under its ABN Amro loan agreement.

This announcement is being made in compliance with Nasdaq Marketplace Rule 4350(b)(1)(B), which requires separate disclosure of receipt of an audit opinion that contains a going concern qualification.

Synutra's Forms 10-K are available online: http://www.synutra.com .

About Synutra International, Inc.

Synutra International, Inc. is a leading infant formula company in China. It principally produces, markets and sells its products under the "Shengyuan," or "Synutra," name, together with other complementary brands. It focuses on selling premium infant formula products, which are supplemented by more affordable infant formulas targeting the mass market as well as other nutritional products and ingredients. It sells its products through an extensive nationwide sales and distribution network covering 29 provinces and provincial-level municipalities in China. As of March 31, 2009, this network comprised over 480 distributors and over 800 sub-distributors who sell Synutra products in over 65,000 retail outlets.

    For more information, please contact:

    Weiguo Zhang of Synutra International, Inc.
     Tel:   +1-301-840-3888
     Email: wzhang@synutra.com
     Web:  http://www.synutra.com

    Delia Cannan of Taylor Rafferty
     Tel:   +1-212-889-4350
     Email: synutra@taylor-rafferty.com

'/>"/>
SOURCE Synutra International, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Nasdaq Informs Synutra that the Companys Filing Delinquency has been Cured
2. Synutra International, Inc. Amends August 2005 Current Report on Form 8-K and Annual Report on Form 10-K for the Fiscal Year Ended March 31, 2007
3. Synutra Provides Progress Update on Recall and Reports Results for the Second Quarter Ended September 30, 2008
4. Synutra Issues Statement Regarding Market Rumors on Revocation of its Production Certification
5. Synutra International, Inc. Sets the Date for its Fourth Quarter and Fiscal Year Earnings Announcement
6. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
7. GPhAs 2007 Annual Policy Conference Features Top Generic Industry CEOs; FDA, Government Officials; Wall Street Analysts
8. Hospira to Present at the Bear Stearns 20th Annual Healthcare Conference on September 11
9. Bear Stearns 20th Annual Healthcare Conference to Webcast Millennium Presentation
10. inVentiv Health to Present at the 20th Annual Bear Stearns Healthcare Conference
11. Annual flu shot cuts need for doctors visits, hospitalization among children
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... ... August 17, 2017 , ... A recent report indicates ... biopharmaceutical industry in 2016 cited deficiencies in data integrity. The FDA outlines their expectations ... ruling. , Presented as part of the Beckman Coulter Life Sciences Virtual ...
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... The next ... now being accepted. , Students who successfully complete the seven-week long Patient Care ... Nurse Assistant (CNA). The average starting salary for a CNA in Kalamazoo is $24,428.* ...
(Date:8/16/2017)... ... 2017 , ... Greenfield Advisors is honored to be named to Inc. Magazine’s ... in a row. The Inc. 5000 list honors private businesses across the country that ... list once is a great accomplishment, but for us to be included again goes ...
(Date:8/16/2017)... ... August 16, 2017 , ... Any Lab Test ... The company ranked #4429 on the newly released, 36th annual Inc. 5000 , ... unique look at the most successful companies within the American economy’s most dynamic segment ...
(Date:8/16/2017)... New York (PRWEB) , ... August 16, 2017 , ... ... could minimize its appearance with diet and exercise. In fact, cellulite can't always be ... a safer and more effective treatment available to select physicians nationwide. Dr. Kenneth Rothaus ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... Aug. 7, 2017 Insightin Health, provider ... retention, and engagement, announced the selection of ... Product Development, effective as of February 2017. In this ... implementation strategy for our clients. Wood brings with ... consulting and business analytics within the healthcare industry. ...
(Date:8/7/2017)...  Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s largest independent ... 30, 2017.  All comparisons, unless otherwise noted, are to the ... Second Quarter 2017 Highlights include: ... increase of 3.5% Total prescriptions dispensed of ... 7.5% versus 7.6% Gross profit per ...
(Date:8/4/2017)... , Aug. 3, 2017  Agragen, LLC, ... company active in the biopharmaceutical, nutraceutical, and aquacultural ... development of its lead drug candidates, AGR131.  This ... proinflammatory cytokine from the blood of patients suffering ... and inflammatory bowel disease. ...
Breaking Medicine Technology: